Amarin Corp Plcuk (AMRN) Accumulated Expenses (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Accumulated Expenses of $131.5 million for Q1 2026, up 12.63% YoY from $116.7 million in Q1 2025, and down 11.81% sequentially from $149.1 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Accumulated Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Accumulated Expenses across 17 years of filings, most recently posting $131.5 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 12.63% year-over-year to $131.5 million; the TTM figure through Mar 2026 stood at $131.5 million (up 12.63% YoY), while the FY2025 annual figure was $149.1 million, up 870.6% from the prior year.
- Accumulated Expenses slipped to $131.5 million in Q1 2026, from $149.1 million in the prior quarter.
- Over the last five years, Accumulated Expenses for AMRN reached as high as $243.1 million in Q2 2022 and fell as low as $3.6 million in Q4 2023.
- The 5-year median for Accumulated Expenses is $154.4 million (2024), against an average of $145.1 million.
- Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 82.33% — and 2025, when it surged 870.6%.
- A 5-year view of Accumulated Expenses shows it stood at $20.3 million in 2022, then sank by 82.33% to $3.6 million in 2023, then jumped by 328.27% to $15.4 million in 2024, then surged by 870.6% to $149.1 million in 2025, then slipped by 11.81% to $131.5 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $131.5 million, $149.1 million, and $145.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131.49 Mn |
| Dec 31, 2025 | 149.10 Mn |
| Sep 30, 2025 | 145.52 Mn |
| Jun 30, 2025 | 141.24 Mn |
| Mar 31, 2025 | 116.75 Mn |
| Dec 31, 2024 | 15.36 Mn |
| Sep 30, 2024 | 161.05 Mn |
| Jun 30, 2024 | 176.16 Mn |
| Mar 31, 2024 | 154.44 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 211.30 Mn |
| Jun 30, 2023 | 214.60 Mn |
| Mar 31, 2023 | 183.26 Mn |
| Dec 31, 2022 | 20.30 Mn |
| Sep 30, 2022 | 192.00 Mn |
| Jun 30, 2022 | 243.06 Mn |
| Mar 31, 2022 | 207.62 Mn |
| Dec 31, 2021 | 3.56 Mn |
| Sep 30, 2021 | 289.68 Mn |
| Jun 30, 2021 | 226.55 Mn |